Last $39.99 USD
Change Today -1.40 / -3.38%
Volume 578.6K
DXCM On Other Exchanges
Symbol
Exchange
DXCM is not on other exchanges.
As of 8:10 PM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

dexcom inc (DXCM) Key Developments

Insulet Corporation and DexCom to Develop CGM-Integrated Diabetes Manager

Insulet Corporation and DexCom, Inc. have agreed to develop a CGM-integrated personal diabetes manager. This will allow information from Dexcom's 5th generation CGM system to be identified, received and displayed on Insulet's new Bluetooth-enabled Personal Diabetes Manager. This project expands upon the initial agreement announced in June to enable the Dexcom mobile app platform to integrate data from Insulet's OmniPod System. That platform to enable glucose and pump data to be displayed on a smartphone.

DexCom, Inc. Announces Data Integration Relationship with Asante Solutions, Inc

Asante Solutions, Inc. and DexCom, Inc. announced their intention to enable the Dexcom mobile app platform, which is currently under development, to integrate and display insulin data from the Asante Snap Insulin Pump. This will be the second insulin delivery device to be integrated into the Dexcom mobile app, which is designed to aggregate glucose and other diabetes-related data from patients' devices and display the integrated data on a smartphone. In June, Dexcom announced its intention to maintain an 'open architecture' approach to diabetes-related data which will include an ‘Authorized by Dexcom’ mark to indicate the compatibility of devices and apps integrating Dexcom CGM data.

DexCom, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

DexCom, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenue of $58.2 million compared to $35.8 million a year ago. Operating loss was $5.8 million compared to $9.9 million a year ago. Net loss was $6.0 million or $0.09 per diluted share compared to $10.1 million or $0.14 per basic and diluted share a year ago. For the six months, the company reported total revenue of $105.9 million compared to $65.4 million a year ago. Operating loss was $18.1 million compared to $20.8 million a year ago. Net loss was $18.5 million or $0.25 per basic and diluted share compared to $21.2 million or $0.30 per basic and diluted share a year ago.

DexCom, Inc., Q2 2014 Earnings Call, Aug 06, 2014

DexCom, Inc., Q2 2014 Earnings Call, Aug 06, 2014

DexCom, Inc. to Report Q2, 2014 Results on Aug 06, 2014

DexCom, Inc. announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Aug 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DXCM:US $39.99 USD -1.40

DXCM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Insulet Corp $36.85 USD -0.75
Merge Healthcare Inc $2.20 USD -0.07
NeuStar Inc $24.83 USD -0.15
Radview Software Ltd $0.0022 USD 0.00
Tandem Diabetes Care Inc $13.42 USD +0.22
View Industry Companies
 

Industry Analysis

DXCM

Industry Average

Valuation DXCM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.5x
Price/Book 31.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DEXCOM INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.